Nasdaq GlobeNewswire

Orion Biotechnology acquires patent portfolio for potent CCR5 chemokine antagonist

Del

OTTAWA, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its subsidiary, Orion Biotechnology Switzerland Sàrl, has successfully closed a transaction with the Mintaka Medical Research Foundation for the acquisition of the 5P12-RANTES molecule. 5P12-RANTES is a potent CCR5 chemokine antagonist which Orion will develop in a number of areas, including immuno-oncology, multiple sclerosis and HIV prevention. 

The acquisition includes its worldwide patent portfolio, and has resulted in a partnership with the Geneva, Switzerland based Mintaka Medical Research Foundation, and the Wellcome Trust of London, England. No financial details of the transaction were released.

“We are thrilled to add the enormous potential of the 5P12-RANTES portfolio to our pipeline,” said Mark Groper, President and CEO of Orion Biotechnology. “It adds depth to our pipeline, strengthens our intellectual property portfolio, and provides the basis for the development of several additional novel immunotherapies.”

“I’m excited that we were able to successfully form this partnership with Orion Biotechnology,” said Robin Offord, Executive Director of the Mintaka Medical Research Foundation. “Mintaka looks forward to continuing its work on humanitarian (anti-HIV) uses of 5P12-RANTES with the help of the highly innovative and capable team at Orion and the substantial resources that they bring to the table.  Also, 5P12-RANTES has surprised us all by its potential in a wide range of other medical indications and Orion is well placed to exploit these applications to the full.”

Daniel Gill, from Wellcome’s Innovations team, said: “HIV remains a significant global health issue and we are pleased to continue our collaboration on the development of 5P12-RANTES with Orion Biotechnology.  5P12-RANTES has significant potential in other areas of unmet need and we are excited that Orion will expand development of the molecule in other therapeutic areas such as immune-oncology and multiple sclerosis.”

About Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd, is a privately held pharmaceutical company which is developing a range of novel medicines aimed at successful treatment and prevention of the most serious illnesses and life-threatening diseases. Since 2011, Orion has been developing a robust pipeline of potential products based on innovations from different parts of the world. Our close ties to diverse institutions and experts around the globe continue to stimulate the rapid discovery of promising new treatments. With operations in North America, Europe and Asia, Orion brings together innovative technologies from some of the world’s leading research institutions such as the Mintaka Foundation for Medical Research and the Center for Public Health Research at Nanjing University. Learn more at www.orionbiotechnology.com.

About Mintaka Foundation for Medical Research
The Mintaka Foundation for Medical Research is a Geneva-based charitable foundation with the goal of ‘using advanced technology to find simple health solutions for developing countries’.  Today the Foundation is focused on three areas of research; Prevention of HIV/AIDS, Prevention of maternal death in childbirth, and next-generation vaccines.  Founded by three professors at Geneva's Faculty of Medicine, Mintaka identifies health problems in the developing world that require high technology research to find a solution, but for which the solution, once found, can be made economically accessible to the most disadvantaged populations on the planet. If successful, the development of 5P12-RANTES might have a significant humanitarian impact in the field of HIV prevention.  Learn more at www.mintakafoundation.org.

About Wellcome
Wellcome exists to improve health for everyone by helping great ideas to thrive. We’re a global charitable foundation, both politically and financially independent. We support scientists and researchers, take on big problems, fuel imaginations and spark debate. Learn more at www.wellcome.ac.uk

Forward-Looking Statements
This press release contains forward-looking information, which reflects Orion’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Orion’s control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Orion assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: Ross MacLeod
Orion Biotechnology Canada Ltd
Phone: +1.343.291.1032
info@orionbiotechnology.com

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

2018 Black Hat Europe Research: Low Confidence in GDPR, Lack of Privacy via Social Media, Impending Nation-Wide Critical Infrastructure Attacks & More14.11.2018 10:00Pressemelding

Register Now Through December 2 to Save £200 on Briefings Pass SAN FRANCISCO, Nov. 14, 2018 (GLOBE NEWSWIRE) -- As the world adapts to GDPR and puts more attention on personal privacy and security, Europe’s top information security professionals still have doubts about the industry’s ability to protect critical infrastructure, corporate networks, and personal information. Black Hat Europe’s new research report entitled, Europe’s Cybersecurity Challenges , details the thoughts that are keeping Europe’s top information security professionals awake at night. The report includes new insights directly from more than 130 survey respondents and spans topics related to GDPR, personal privacy, current industry challenges, and what Europeans should anticipate in the years to come. Is GDPR Worth the Effort? While respondents noted that the General Data Protection Regulation (GDPR), implemented in May, is top of mind, there is an emerging lack of confidence in its potential effectiveness. There is

Standard Lithium Announces Maiden Inferred Resource of 3,086,000 Tonnes LCE at Southern Arkansas Project14.11.2018 09:01Pressemelding

VANCOUVER, British Columbia, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L), is pleased to report a maiden lithium resource statement for its 150,000 acre Project in the south-central region of Arkansas, USA (the “Property”; see Company news release 9th May 2018). The maiden resource report, detailed in Table 1 below, includes 3,086,000 metric tonnes of lithium carbonate equivalent (LCE) at the Inferred Resource category (see notes [4] and [5] below). Table 1 – South Arkansas Lithium Brine Project Inferred Resource Statement Parameter South Unit Central Unit West Unit Total Aquifer Volume (km3) 5.83 8.29 16.31 30.43 Brine Volume (km3) 0.689 0.995 1.84 3.52 Average Li concentration Milligrams per litre (mg/L) 165 mg/L Average Porosity 11.8% 12.0% 11.2% 11.6% Total Li resource (as metal) metric tonnes (see notes [4] & [5] below) 114,000 164,000 303,000 580,000 Total LCE resource (metric tonnes) (see note

LeddarTech’s Mobility Leadership Series Addresses Autonomous Driving and LiDAR Technologies in Europe14.11.2018 06:01Pressemelding

QUEBEC CITY, Nov. 14, 2018 (GLOBE NEWSWIRE) -- LeddarTech, an industry leader in providing the most versatile and scalable automotive LiDAR development platform, announces that as part of the LeddarTech Mobility Leadership Series, two of its experts, Pascal Tousignant, senior product line manager and Frantz Saintellemy, president and COO, will take the stage at two different key European industry events this month : the DVN Conference on LiDAR and the Telegraph Smart Mobility Summit 2018. DVN Conference on LiDAR On November 20, 2018, in Frankfurt, Germany, LeddarTech’s Senior Product Line Manager Pascal Tousignant will present Demystifying LiDAR Technologies and Business Models for Automotive AD Applications. This presentation explains LeddarTech’s technology choices and their competitive advantages. It also provides details on the LeddarTech LiDAR solution that enables customers to design custom automotive LiDARs with the leverage of LeddarTech’s reliable, safe and flexible platform.

Algeco Enters Into Definitive Agreement to Sell Target Lodging14.11.2018 00:59Pressemelding

LONDON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Algeco Investments B.V. (“Algeco Investments”, and together with its subsidiaries, “Algeco”), the leading global business services provider of modular space, secure portable storage solutions and remote workforce accommodations, today announced that certain of its subsidiaries have entered into a definitive agreement (the “Stock Purchase Agreement”) with Platinum Eagle Acquisition Corp., a publicly traded special purpose acquisition company (“PEAC”), to sell the Algeco Group’s North American remote accommodations business, Target Lodging, to Target Lodging Holdings Corp. (“Holdco”), a newly-formed subsidiary of PEAC (the “Transaction”). Simultaneously to the Target Lodging sale, TDR Capital LLP will be selling its Signor Holdings business to PEAC as well. Andrew Tyler, CEO Algeco: “We are very excited about the sale of Target Lodging to Platinum Eagle Acquisition Corp. This sale captures significant value for Algeco and allows Algeco to continu

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom